

[This information is provided by 3176 Medigen Biotech Corp. \(TPEX Listed Company\)](#)

Item	1	Announcement Date	2021/04/15	Announcement Time	19:06:29
Spokesperson	Arlene Chiang	Spokesperson Position	Assistant Vice President, Operations Department	Contact Information	[02]2653-5200#890
Subject	Taiwan Ministry of Health and Welfare (MOHW) approves the collaborative autologous NK cell therapy project by the Company and the Shin Kong Hospital				
Pursuant To Article	4	Subparagraph	53	Date of occurrence of event	2021/04/15
Details	<ol style="list-style-type: none"> <li>1. Date of occurrence of the event: 2021/04/15</li> <li>2. Company name: Medigen Biotechnology Corporation</li> <li>3. Relationship with the Company (please enter "the company itself" or "subsidiaries"): The Company itself.</li> <li>4. Reciprocal shareholding percentage: NA</li> <li>5. Cause of occurrence: The cell processing unit (CPU) within the Company's GTP laboratory is the CPU contracted by the Shin Kong Wu Ho-Su Memorial Hospital (abbreviated as Shin Kong Hospital) in its autologous NK cell (Magicell-NK) therapy project for the treatment of stage IV solid tumors submitted to the MOHW, in compliance with the "Regulation Governing the Application of Specific Medical Examination Technique and Medical Device". The Company has received the approval letter from MOHW on April 15, 2021, confirming that the CPU within the Company's GTP laboratory complies with Good Tissue Practice.</li> <li>6. Countermeasures: Release material information as instructed by the approval letter from MOHW.</li> <li>7. Any other matters that need to be specified: <ol style="list-style-type: none"> <li>(1) Details on the approved items in the abovementioned Shin Kong Hospital's cell therapy project: <ol style="list-style-type: none"> <li>A. Type of cell therapy: Autologous Natural Killer Cell (Magicell-NK)</li> <li>B. Indication: Stage IV solid tumors; Colorectal Cancer, Lung Cancer, Breast Cancer, Liver Cancer, Head and Neck Cancer, Prostate Cancer, Pancreatic Cancer, Esophageal Cancer, Ovarian Cancer and Brain Cancer.</li> <li>C. Cell Processing Unit: Medigen Biotechnology Corp. Cell Processing Unit</li> <li>D. Effective Period: From 2021/04/15 to 2023/02/02</li> </ol> </li> <li>(2) The Company's autologous NK cell therapy project has been approved for use in the following medical institutions: E-Da Cancer Hospital, Hualien Tzu Chi Hospital, Chi Mei Medical Center, Jen-Ai Hospital Dali Branch and Changhua Christian Hospital.</li> <li>(3) The application for the Company's collaborative Gamma-Delta T-cell therapy project with Shin Kong Hospital has been submitted on November 02, 2020.</li> </ol> </li> </ol>				

The above information is declared by the company in accordance with the regulations of the market it belongs to at the time, and released to the public through this system. The company shall hold sole responsibility if any false information is declared.